Home

Eli Lilly (LLY)

713.71
-1.49 (-0.21%)
NYSE · Last Trade: May 25th, 3:51 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Value Investing Is Not Dead - It Just Got Smarterbenzinga.com
Via Benzinga · May 23, 2025
3 Trades Members of Congress Are Making Right Now
Knowing what Congressional leaders are buying can give investors insight into future legislation that could benefit these companies
Via MarketBeat · May 23, 2025
Investing for the Long Term: 1 Unstoppable Vanguard ETF to Buy and Hold Foreverfool.com
Via The Motley Fool · May 23, 2025
Huge News for Eli Lilly Stock Investors!fool.com
Via The Motley Fool · May 18, 2025
2 Growth Stocks to Own for Decades and 1 to Steer Clear Of
Growth is oxygen. But when it evaporates, the consequences can be extreme - ask anyone who bought Cisco in the Dot-Com Bubble (Nvidia?) or newer investors who lived through the 2020 to 2022 COVID cycle.
Via StockStory · May 23, 2025
5 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · May 22, 2025
Hims & Hers Stock Drops After Evernorth Announces Cheaper Pricing For Weight-Loss Drugs: Retail’s Dullstocktwits.com
Truist noted on Thursday that the $200/month price point is "highly attractive compared to other price points in the market," including Hims & Hers' compounded Semaglutide, Wegovy, and Liraglutide subscription programs.
Via Stocktwits · May 22, 2025
Better Weight Loss Stock: Amgen or Viking Therapeutics?fool.com
Via The Motley Fool · May 22, 2025
Did Eli Lilly Just Say Checkmate to Novo Nordisk?fool.com
Via The Motley Fool · May 22, 2025
Is the Vanguard Dividend Appreciation ETF a Buy Now?fool.com
Via The Motley Fool · May 22, 2025
Wegovy, Zepbound Just Got Cheaper: Cigna Sets $200 Monthly Limit For Weight-Loss Drug Usersstocktwits.com
Cigna’s Evernorth has reached agreements with Eli Lilly and Novo Nordisk to reduce prices for GLP-1 weight-loss drugs Wegovy and Zepbound
Via Stocktwits · May 22, 2025
Eli Lilly Options Trading: A Deep Dive into Market Sentimentbenzinga.com
Via Benzinga · May 21, 2025
Best Healthcare Stocks: Eli Lilly vs. Novo Nordiskfool.com
Via The Motley Fool · May 21, 2025
Trump's $6 Trillion Investment Deals Face Reality Check: Only A Fraction May Reach The Real Economybenzinga.com
Despite $6 trillion in promised investments under Trump, Goldman Sachs estimates only $30B–$135B will meaningfully impact U.S. GDP.
Via Benzinga · May 20, 2025
Marjorie Taylor Greene Goes Shopping For Tesla, Netflix, UnitedHealth And More: 19 Stocks The Congresswoman Boughtbenzinga.com
Marjorie Taylor Greene disclosing buying 19 different stocks in a new filing. The buys come less than two weeks after the purchase of 50 different stocks.
Via Benzinga · May 20, 2025
10 Health Care Stocks With Whale Alerts In Today's Sessionbenzinga.com
Via Benzinga · May 20, 2025
Apple, Nvidia, GM: CEOs Are Talking About Being American-Made Againbenzinga.com
US companies are reshoring manufacturing operations & investing billions in the country, led by Apple & Nvidia for tech, J&J & Eli Lilly for healthcare, Anheuser-Busch for beer, & Cra-Z-Art for toys. Detroit & beyond are benefiting from this trend.
Via Benzinga · May 20, 2025
Great News for Eli Lilly Stock Investors!fool.com
Via The Motley Fool · May 20, 2025
The End Of The Diabetes Industry? This Small Cap Could Upend The Business Models of Pharma Giantsbenzinga.com
is it the end of the diabetes industry? Here's a small cap that could upend the business models of pharma giants...
Via Benzinga · May 19, 2025
23andMe Finds A Big Biotech Buyer In $256 Million Bankruptcy Auctioninvestors.com
The acquirer says it will continue 23andMe's consumer genome testing services. It acquired a number of programs, including the biobank.
Via Investor's Business Daily · May 19, 2025
The Nasdaq Just Soared 30% From Its 2025 Low: 3 Vanguard ETFs to Buy Nowfool.com
Via The Motley Fool · May 18, 2025
Why Is Eli Lilly Stock Crashing and Is It a Buying Opportunity?fool.com
Via The Motley Fool · May 18, 2025
Got $1,000 to Invest? Buy This Top Vanguard ETF and Never Look Back.fool.com
Via The Motley Fool · May 17, 2025
MarketBeat Week in Review – 05/12 - 05/16
Stocks had a strong week on a potential U.S.-China trade deal and cooler inflation data, but volatility may remain as investors shift focus to tax cuts
Via MarketBeat · May 17, 2025
Eli Lilly Pulls Ahead Of Novo In Obesity Drug Gold Rush As New Players Crowd Intalkmarkets.com
Eli Lilly has steadily gained market share against Novo's Wegovy which finds itself catching up.
Via Talk Markets · May 16, 2025